CONSUMER RIGHTS IN NEURO-INTERACTION THERAPIES: LEGAL PROTECTION, DATA PRIVACY AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Neuro-interaction therapies involve technologies and therapeutic interventions that establish interaction between the human nervous system and external devices, software or digital platforms. These include brain-computer interfaces (BCIs), neurofeedback systems, neural stimulation devices, neurological rehabilitation technologies and other neurotechnology-based treatments.

Such therapies may be used for neurological rehabilitation, movement disorders, cognitive assistance and other medical applications. However, they also create important consumer-protection concerns involving patient safety, misleading therapeutic claims, unauthorised collection of neural information, defective devices and inadequate disclosure of treatment risks.

Consumers using neuro-interaction therapies are entitled to protection against defective products, deficient medical services, unfair commercial practices and misuse of personal information. Indian consumer law, constitutional privacy principles and medical regulatory requirements provide important safeguards.

2. LEGAL FRAMEWORK GOVERNING CONSUMER RIGHTS

A. CONSUMER PROTECTION ACT, 2019

The Consumer Protection Act, 2019 protects consumers against defective goods, deficient services, unfair trade practices and misleading advertisements. Its product-liability provisions may apply to defective neuro-interaction devices and qualifying services.

B. CONSTITUTIONAL PROTECTION UNDER ARTICLE 21

Article 21 protects life, personal liberty and privacy. The constitutional right to privacy is particularly relevant when neuro-interaction technologies collect information concerning brain activity, neurological functioning or cognitive responses.

C. MEDICAL DEVICE REGULATION

The Medical Devices Rules, 2017, under the Drugs and Cosmetics Act, 1940, provide the regulatory framework for medical devices in India. Applicable requirements depend on the device's classification, intended purpose and regulatory status.

D. DIGITAL PERSONAL DATA PROTECTION ACT, 2023

The Act provides a framework for processing digital personal data, including applicable requirements concerning consent, lawful processing, security safeguards and individual rights. Neural information may fall within its scope when it constitutes digital personal data.

E. MEDICAL ETHICS AND RESEARCH REGULATION

Healthcare professionals and research institutions must comply with applicable medical ethics, clinical research requirements and informed-consent obligations. Research involving neuro-interaction technologies may require independent ethics committee review.

3. FUNDAMENTAL CONSUMER RIGHTS

1. RIGHT TO SAFETY

Consumers are entitled to protection against unsafe neuro-interaction devices, defective electrodes, malfunctioning stimulation equipment and inadequately tested therapeutic systems.

2. RIGHT TO INFORMATION

Consumers must receive accurate information about device functionality, treatment objectives, material risks, limitations, expected outcomes and maintenance requirements.

3. RIGHT TO CHOOSE

Patients should be informed about reasonable alternative treatments and should not be compelled to purchase a particular neurotechnology product through misleading representations or coercive commercial practices.

4. RIGHT TO PRIVACY

Consumers have legitimate interests in protecting neural recordings, neurological assessments and other personal information from unauthorised collection, disclosure or exploitation.

5. RIGHT TO BE HEARD

Consumers must have access to appropriate complaint mechanisms and opportunities to challenge defective products, inadequate services and unfair commercial practices.

6. RIGHT TO SEEK REDRESSAL

Consumers may seek legally available remedies, including replacement, refund, compensation and other appropriate relief for established consumer-law violations.

7. RIGHT TO TRANSPARENCY

Providers must clearly disclose subscription charges, device limitations, software updates, data-sharing arrangements and additional treatment costs.

4. MAJOR CONSUMER-PROTECTION ISSUES

A. DEFECTIVE NEURO-INTERACTION DEVICES

Hardware failures, electrode defects, inaccurate measurements and software malfunctions may cause injury or compromise treatment. Manufacturers and other responsible parties may face liability under applicable product-liability principles.

B. MISLEADING THERAPEUTIC CLAIMS

Companies must not falsely promise guaranteed cognitive enhancement, permanent neurological recovery or complete restoration of brain function without adequate scientific support.

C. UNAUTHORISED NEURAL DATA COLLECTION

Collecting or commercially exploiting neural information beyond the disclosed purpose may raise privacy, consent and consumer-protection concerns.

D. INADEQUATE RISK DISCLOSURE

Consumers should receive information about relevant risks, including discomfort, skin irritation, device-related complications, inappropriate stimulation and limitations of clinical evidence.

E. DEFICIENT HEALTHCARE SERVICES

Hospitals and rehabilitation centres may face liability where negligent operation, inadequate supervision or failure to follow appropriate professional standards causes legally recognised harm.

F. UNFAIR SUBSCRIPTION AND LICENSING PRACTICES

Consumers should be protected against hidden fees, misleading subscription terms, unauthorised automatic renewals and unreasonable restrictions on access to purchased devices or services.

5. IMPORTANT JUDICIAL PRECEDENTS

The following judgments establish relevant principles of consumer protection, medical negligence, informed consent, privacy and product accountability.

1. Indian Medical Association v. V.P. Shantha (1995), Supreme Court of India — Direct consumer-law authority

The Supreme Court recognised that medical services provided for consideration generally fall within consumer-protection legislation. This judgment supports the right of patients receiving paid neuro-interaction therapy to seek redressal for deficient medical services.

2. Samira Kohli v. Dr. Prabha Manchanda (2008), Supreme Court of India — Direct authority on informed consent

The Court explained that medical consent must be voluntary and informed and that consent for one procedure does not automatically authorise a substantially different procedure. This principle applies when a patient authorises a particular neuro-interaction treatment but receives an unauthorised additional intervention.

3. Justice K.S. Puttaswamy v. Union of India (2017), Supreme Court of India — Analogous constitutional authority

The Supreme Court recognised privacy as a fundamental right under Article 21. Its principles are particularly relevant to neural recordings, brain activity measurements and cognitive information collected through neuro-interaction devices.

4. Jacob Mathew v. State of Punjab (2005), Supreme Court of India — Direct medical-negligence authority

The Court explained the standards governing professional negligence and the duty of medical practitioners to exercise reasonable skill and care. This judgment is relevant where improper operation, inadequate supervision or negligent use of neuro-interaction devices causes patient injury.

5. Spring Meadows Hospital v. Harjol Ahluwalia (1998), Supreme Court of India — Direct consumer-law authority

The Supreme Court considered medical negligence and recognised consumer remedies arising from deficient healthcare services. Its principles support compensation claims where neurotechnology-based treatment causes injury through negligent medical management.

6. Indian Medical Association v. Union of India (2024), Supreme Court of India — Authority on misleading healthcare advertisements

The Court examined misleading medical advertisements and the responsibilities of manufacturers, advertisers and endorsers. Its principles apply to companies making unsupported claims about brain enhancement, neurological recovery or the guaranteed effectiveness of neuro-interaction therapies.

7. Jaita Mitra Basu v. Dr. Anirban Chatterjee and Nightingale Diagnostic & Medicare Centre Pvt. Ltd. (2025), NCDRC — Direct consumer-law authority

The National Consumer Disputes Redressal Commission addressed the inadequacy of generic high-risk consent in a medical procedure. It emphasised patient-specific informed consent and recognised that failure to obtain adequate consent may constitute deficiency in service. This is relevant to invasive neuro-interaction procedures requiring disclosure of individual risks. <Cite refs={["turn665490search24"]}/>

8. Dr. S.K. Jhunjhunwala v. Dhanwanti Kaur (2018), Supreme Court of India — Analogous authority

The Court examined the scope of consent for a substituted surgical procedure and considered the circumstances in which the original consent authorised an alternative procedure. Its reasoning is relevant when assessing whether a neuro-interaction provider has exceeded the treatment authorisation given by a patient. <Cite refs={["turn665490search6"]}/>

6. PRODUCT LIABILITY AND COMPENSATION

Under the Consumer Protection Act, 2019, product-liability claims may arise against manufacturers, product sellers and service providers where the statutory conditions are satisfied.

Potential grounds include:

Manufacturing defects in neural recording equipment.

Design defects in brain-computer interface devices.

Inadequate warnings concerning device-related risks.

Defective software affecting therapeutic performance.

Failure to provide appropriate instructions.

Negligent installation, operation or maintenance.

Misrepresentation of therapeutic effectiveness.

Consumers may seek appropriate remedies, including replacement, refund, compensation, discontinuation of unfair practices and other relief available under the legislation.

7. REGULATORY AND INSTITUTIONAL RESPONSIBILITIES IN INDIA

The following regulatory frameworks are particularly relevant:

Consumer Protection Act, 2019: Provides remedies against defective goods, deficient services, misleading advertisements and unfair trade practices.

Medical Devices Rules, 2017: Regulate applicable medical devices, including relevant electrical and software-based therapeutic devices. <Cite refs={["turn665490search0","turn665490search1"]}/>

Drugs and Cosmetics Act, 1940: Provides the statutory framework for regulated medical products and devices.

Digital Personal Data Protection Act, 2023: Establishes applicable obligations concerning digital personal data processing and protection.

Rights of Persons with Disabilities Act, 2016: Provides relevant protections for individuals with disabilities who may use neurotechnology-based assistive systems.

ICMR National Ethical Guidelines: Provide ethical standards for biomedical and health research involving human participants.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Neuro-interaction therapy providers should adopt the following measures:

Verify the regulatory status and safety of therapeutic devices.

Explain the purpose and limitations of the technology.

Obtain specific and informed patient consent.

Disclose foreseeable neurological and device-related risks.

Protect neural recordings against unauthorised access.

Provide transparent pricing and subscription conditions.

Maintain device maintenance and treatment records.

Establish adverse-event reporting procedures.

Avoid unsupported claims concerning cognitive enhancement or neurological recovery.

Provide accessible complaint-handling and compensation mechanisms.

9. CONCLUSION

Consumer rights in neuro-interaction therapies are essential because these technologies involve the interaction of medical devices, digital systems and sensitive neurological information. Consumers must receive protection against defective equipment, misleading therapeutic claims, negligent treatment, unfair commercial practices and unauthorised use of personal neural information.

The principles established in Indian Medical Association v. V.P. Shantha, Samira Kohli, Puttaswamy, Jacob Mathew and Spring Meadows Hospital provide important legal foundations for consumer protection and medical accountability.

Ultimately, effective regulation of neuro-interaction therapies requires device safety, informed consent, transparent commercial practices, protection of neural privacy and accessible legal remedies. The objective must be to ensure that technological innovation does not undermine consumer autonomy, dignity, safety or fundamental rights.